Cargando…

Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010)

The global phase 3 IMpower010 study evaluated adjuvant atezolizumab versus best supportive care (BSC) following platinum‐based chemotherapy in patients with resected stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report a subgroup analysis in patients enrolled in Japan. Eligible patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kenmotsu, Hirotsugu, Sugawara, Shunichi, Watanabe, Yasutaka, Saito, Haruhiro, Okada, Morihito, Chen‐Yoshikawa, Toyofumi Fengshi, Ohe, Yuichiro, Nishio, Wataru, Nakagawa, Shizuka, Nagao, Haruka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746048/ https://www.ncbi.nlm.nih.gov/pubmed/36062851 http://dx.doi.org/10.1111/cas.15564

Ejemplares similares

IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
por: Nishio, Makoto, et al.
Publicado: (2021)

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials
por: Socinski, Mark A., et al.
Publicado: (2023)

Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
por: Remon, Jordi, et al.
Publicado: (2020)

Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
por: De Giglio, Andrea, et al.
Publicado: (2019)

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
por: Zhou, Caicun, et al.
Publicado: (2023)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer
por: Lu, Shun, et al.
Publicado: (2022)

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
por: Liu, Stephen V., et al.
Publicado: (2021)

Ischemia–Reperfusion Injury in Lung Transplantation
por: Chen-Yoshikawa, Toyofumi Fengshi
Publicado: (2021)

Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status
por: Isaka, Tetsuya, et al.
Publicado: (2022)

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Commentary: Less is more in thoracic surgery
por: Okado, Shoji, et al.
Publicado: (2022)

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
por: West, Howard Jack, et al.
Publicado: (2022)

OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study
por: Cui, ChuanLiang, et al.
Publicado: (2022)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Lessons learned from hybrid surgery with preoperative coil embolization for an aberrant artery in pulmonary sequestration
por: Nakanishi, Keita, et al.
Publicado: (2021)

A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis
por: Ikeda, Satoshi, et al.
Publicado: (2020)

Cost–effectiveness of adjuvant atezolizumab for patients with stage II–IIIA PD-L1+ non-small-cell lung cancer
por: Das, Millie, et al.
Publicado: (2023)

Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors
por: Mizugaki, Hidenori, et al.
Publicado: (2016)

Polyglycolic acid sheet covering to prevent recurrence after surgery for spontaneous pneumothorax: a meta-analysis
por: Kadomatsu, Yuka, et al.
Publicado: (2021)

A novel system applying artificial intelligence in the identification of air leak sites
por: Kadomatsu, Yuka, et al.
Publicado: (2022)

P010 Abstract Withdrawn
Publicado: (2021)

Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
por: Wang, Bing-Yen, et al.
Publicado: (2016)

IMPOWER: a national patient-generated registry for intestinal malrotation exploring diagnosis, treatment, and surgical outcomes
por: Martinez, Sydney A., et al.
Publicado: (2023)

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2021)

Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176
por: Auclin, Edouard, et al.
Publicado: (2021)

Case-Control Study of Platelet Glycoprotein Receptor Ib and IIb/IIIa Expression in Patients with Acute and Chronic Cerebrovascular Disease
por: Kraft, Peter, et al.
Publicado: (2015)

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC
por: Crandall, John P., et al.
Publicado: (2017)

IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
por: Huang, Chengliang, et al.
Publicado: (2020)

Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T
por: Dorff, Tanya, et al.
Publicado: (2021)

DICE Manual Version 0.10
por: Dell'Acqua, A
Publicado: (1995)

Challenges in left sleeve pneumonectomy in the left lateral decubitus position
por: Nakamura, Shota, et al.
Publicado: (2022)

Postoperative empyema complicated with descending necrotizing fasciitis: a case report
por: Kadomatsu, Yuka, et al.
Publicado: (2022)

Clinical application of resection process map as a novel surgical guide in thoracic surgery
por: Kadomatsu, Yuka, et al.
Publicado: (2023)

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
por: Morschhauser, Franck, et al.
Publicado: (2021)

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases
por: Hecht, J.R., et al.
Publicado: (2023)

A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study
por: Ikeda, Satoshi, et al.
Publicado: (2020)

Title unknown, CERN-ALEPH-2001-010
por: CERN. Geneva. ALEPH
Publicado: (2001)

Title unknown, CERN-ALEPH-98-010
por: CERN. Geneva. ALEPH
Publicado: (1998)

CTLA-4 based therapy (MDX-010)
por: Korman, A
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_g9rbu9bjq52b7gpvjaeitrd7ih